Safety evaluation of the DTaP5-IPV-Hib-HepB vaccine: a review.
Francesca FortunatoDomenico MartinelliPier Luigi LopalcoRosa PratoPublished in: Expert opinion on drug safety (2021)
Based on the available data, the DTaP5-IPV-Hib-HepB vaccine has demonstrated a good safety profile, similar to that of other approved penta- and hexavalent vaccines. Rather, post-marketing data are limited and are frequently reported in combination with other hexavalent vaccines or are not adjusted for shares of vaccines use. Neither relevant interferences with other co-administered pediatric vaccines nor safety issues in premature infants have been shown.